This section helps authors, editors, reviewers, advertisers, and other users download important documents. Most documents can be downloaded freely, but some documents need to fill out small registration forms. All red-colored attachments need registration to download.

2024- Journal Subscription Rates- India
(Last updated 07-Oct-2024)

2024- Journal Subscription Rates- Outside India
(Last updated 07-Oct-2024)

2025- Journal Subscription Rates- India
(Last updated 07-Oct-2024)

2025- Journal Subscription Rates- Outside India
(Last updated 07-Oct-2024)

GOC Rates- August 2024
(Last updated 07-Oct-2024)

GST Certificate
(Last updated 07-Oct-2024)

MSME Certificate
(Last updated 07-Oct-2024)

Payment Methods
(Last updated 07-Oct-2024)

Red Flower Publications- Registration Certificate
(Last updated 07-Oct-2024)

Vendor Registration Form
(Last updated 07-Oct-2024)

Assessment Sheet for Evaluator
(Last updated 09-Oct-2024)

Author Declaration and Copyright Transfer Form
(Last updated 09-Oct-2024)

Book authors guidelines
(Last updated 07-Oct-2024)

Books- Permission confirmation form
(Last updated 07-Oct-2024)

Guidelines for Book Proposal Submissions
(Last updated 09-Oct-2024)

Guidelines for Conference Proceedings
(Last updated 09-Oct-2024)

Journal author guidelines
(Last updated 07-Oct-2024)

No Ethical Issues Involved
(Last updated 09-Oct-2024)

Reference Styles
(Last updated 07-Oct-2024)

Template for Case Reports
(Last updated 07-Oct-2024)

Template for Clinical Images
(Last updated 07-Oct-2024)

Template for Editorial
(Last updated 07-Oct-2024)

Template for Letter to Editor
(Last updated 07-Oct-2024)

Template for Original Article
(Last updated 07-Oct-2024)

Template for Review Article
(Last updated 07-Oct-2024)

Template for Short Communications
(Last updated 07-Oct-2024)

Undertaking article made from thesis
(Last updated 07-Oct-2024)

CONSENT FORM FOR EDITORIAL BOARD MEMBER/REVIEWER
(Last updated 27-Jan-2025)

Space Booking Rates
(Last updated 09-Oct-2024)

• Manuscripts can be received and processed at anytime and anywhere
• Automated e-mail notifications
• Authors, editors and reviewers can work from any PC
• Reduced time for peer review and processing of submitted manuscripts

• This is the online manuscript management site
• Why online?
  • Eliminating the use of mail and couriers;
  • Manuscripts can be received and processed anywhere
  • Editors and reviewers can work from any PC
  • Automated e-mail notifications
  • Net result reduced peer review and processing time of submitted manuscripts;
  • Secure and easy to use;

• The system provides the opportunity to submit articles together with images.
• Once submitted, articles can be tracked by progress during the review process until publication.
• Editors' comments can be checked from the site and revised articles can be submitted in a single click.
• The proofs are also managed through this system.
• Authors can manage multiple submissions from a single user interface.
• Registration of new authors: If you have not registered on this site before, click here or on "Register of new authors?" from the main page.

• The system provides "anytime" and "where" access to manuscripts;
• The Reviewers have access to pre-formatted MEDLINE results;
• Can review comments of other reviewers and receive feedback on the decisions on manuscripts;
• Can mark oneself as non-available during a certain period;
• If you are a journal reviewer and you have not received your user name and password, please contact us at author@rfppl.co.in.

• Prior to submitting the manuscript from the website, you need to register with the system. Registration is a two-step process.
• From the site's homepage, click on "New Author Registration" and fill in the details required.
• You will receive an email informing you of the need to confirm your registration by clicking on a specific URL.
• This second verification step is required to complete your registration.
• If you have not registered with the site before, you need to click here or click on "Registration of New Authors" on the main page.

• Please enable cookies and JavaScript in the web browser.
• If you receive a message suggesting that the security certificate is invalid (old web browsers are not compatible with the security certificate), please ignore it.
• If you forgot your password, use "Forgot Password?" on the home page to receive a password on your email account.

• If you need help, assistance or more information, please call us on +91-9821671871, Phone: +91-11-79695648, or email at author@rfppl.co.in
• To find out more about the journals, visit our website at http://www.rfppl.co.in

The Publisher

Mr A. Lal is Director General of Red Flower Publications Private Limited. It regulates all business at the executive level, including employee recruitment, dismissal, compensation, and important decisions for the company. All employees, staff, etc. work under his supervision.

The Managing Editorial Team

This group is responsible for all editorial work, including special sections such as art, editorial and production. However, all these areas are divided into two main categories:

• Editor-in-Chief
  This is the position of the editor and is considered to be the head of the editing team. He is responsible for controlling the main content of the production and plays an essential role in budgetary decisions and contributes to hiring other editors.
• Editors Department
  The second line of the editorial team after the Editor-in-Chief is the editors. It is part of the editorial management team responsible for manuscripts and other publishing documents, and for the editing and copyediting of manuscripts and other publishing documents and providing an alternative for the authors. Editors play an important role in finalizing books and articles in journals.

Art Department

The management team's art department focuses on the design of the cover of the book, both inside and outside. They design, but the sales and marketing departments approve the covers. The head of the editorial department is responsible for designing.

Production Department

This class is responsible for the physical production of books and journal issues, which includes the physical materials that make up the books and journals. Physical entities such as book binding methods and journal issue binding methods, paper stock, cut size, page signatures, number of pages, etc. It plays an essential role, as the cost of producing books and journals will have a huge impact on the editor's statements of profits and losses.

The Proof-reader

Proof-readers are the next in the publisher hierarchy and are responsible for proofreading. He is responsible for assessing grammatical errors, including improving the syntax of sentences, determiners, vocabulary, clarity, spelling errors. This is a complete job that requires time.

The Literary Agent

This is an employee responsible for supporting the publication of literature and overseeing the payment process of books and journals to the author. Their work as agents is to follow-up and pursue contracts with unpublished authors. Many literary agents work in publishing companies in a variety of literary genres. These agents are classified by the type of books and journals they work with.

The Creative Experts

This is a team of individuals who specialize in all artistic designs and drawings needed.

The Marketing Team

This group is responsible for implementing the appropriate marketing strategies of the publisher. Their work includes creating promotional and advertising campaigns.

The Financers

Last but not least, the people responsible for the financial aspects of the publishers are accountants and financial experts.

Last updated 08 October, 2024

The Red Flower Publication Private Limited was founded in New Delhi by Mr. A. Lal, a 36-year-old Meerut University post-graduated and Library and Information Sciences post –graduated from IGNOU (New Delhi) who had previously held a publishing -related job at India’s prestigious medical institution “All India Institute of Medical Sciences, New Delhi. After leaving the job from AIIMS, New Delhi in February, 2000 he started a library supply agency and after serving hundreds of libraries including universities in India and abroad he started a India’s number 1 peer-reviewed journal “Indian Journal of Library and Information Science” in 2007.

In 2008, he started 6 medical super speciality journals. In 2009 he formed a publishing company “Red Flower Publication Private Limited” and immediate its formation the company started 4 more peer reviewed journals. The company by the supervision of Mr.Lal currently publishing 61 medical and scientific journals which are circulated worldwide. The Red Flower Publication Private Limited published relatively few books per year and issued only titles in which the firm's owner himself believed.

• All advertisements are subject to the approval of the Red Flower Publication, which reserves the right to reject or cancel any ad at any time. All advertisements and commercially sponsored publications are independent from editorial decisions. Red Flower Publication does not endorse any product or service marked as an advertisement or promoted by a sponsor in Red Flower Publication. Editorial content is not compromised by commercial or financial interests, or by any specific arrangements with advertising clients or sponsors.
• All advertisements are accepted and published by Publisher on the warranty of the agency and advertiser that both are authorized to publish the entire contents and subject matter of the advertisement.
• All advertisements for drug specific campaigns should encourage correct and rational use and must not be misleading.
• In consideration of the publication of an advertisement, the advertiser and the agency, jointly and severally, agree to indemnify and hold harmless the Publisher, its officers, agents and employees against expenses (including legal fees) and losses resulting from the publication of the contents of the advertisement, including, without limitation, claims or suits for libel, violation of privacy, copyright infringement or plagiarism.
• Publisher will not be liable for any failure to publish any advertisement accepted by Publisher; however, Publisher shall use its reasonable efforts to place such advertisement in subsequent available space.
• All advertisements must clearly and prominently identify the advertiser by trademark or signature. For advertorial guidelines contact your Sales Manager.
• Any references to Publisher or its products or services in advertisements, promotional material, or merchandising by the advertiser or agency are subject to Publisher’s written approval for such use.
• All advertising contract position clauses are treated as requests. Publishers cannot guarantee fixed positioning.
• The publisher is not responsible for incidental or consequential damage for errors in displaying or printing an ad.
• Publisher may change the terms set forth herein at any time, provided that no such change applies to ads whose closing date precedes the announcement of the change.
• Publisher will not be bound by any condition, printed or otherwise, appearing on any insertion order or copy instructions when such conditions conflict with the conditions set forth in this rate card.
• In the event of non-payment, Publisher reserves the right to hold advertiser and/or its advertising agency jointly and severally liable for such money as are past due and payable to Publisher. Red Flower Publication reserves the right to decline any type of advertising that is damaging to the brand of Red Flower Publication or is inappropriate to the content held on the Red Flower Publication network.
• Proprietary names of pharmaceutical products must be accompanied by the chemical, generic or official name; the quantity of all active substances must be stated along with the recommended dosage. New ad copy and creative for pharmaceutical products should be sent to the advertising department. Please allow two weeks for clearance.
• All advertisements must be clearly germane to the practice of medicine.
• Advertiser represents and warrants that all advertisements and pharmaceutical products they advertise are compliant with all applicable laws, rules, and regulations in the country where the advertisement will be seen. Advertisements for pharmaceutical products (including NDA products) that are subject to India Food and Drug Administration (FDA) oversight must comply with FDA regulations regarding advertising and promotion.
• Red Flower Publication will not allow any treatment-specific or drug-specific campaign to be targeted to a specific article(s) or on any page where content relates to the product(s) being advertised. (Advertisers may not link to articles using keywords; they may not target advertising for a specific product on the condition that it appear in the same location and at the same time as a specific article mentioning that product and they may not refer to an article published at the same time as the advertisement appears).
• Once an advertisement has been deployed online, it will be withdrawn from the journal site at any time if the Editor(s)-in-Chief or Publisher request its removal.
• Any use of Publisher’s trademarks and its logo design or copyrighted material for links to and from a Publisher’s website must be approved in advance by Publisher. Publisher does not endorse or support any product or organization linked to its website, nor is Publisher responsible for the content of any website promoted in any advertisement appearing on a Publisher website.
• Advertisements may not be deceptive or misleading, and must be verifiable. Advertisements should clearly identify the advertiser and the product or service being offered. Exaggerated or extravagantly worded copy will not be allowed. Advertisements will not be accepted if they appear to be indecent or offensive in either text or artwork, or if they relate to content of a personal, racial, ethnic, sexual orientation, or religious nature.
• All advertisements at RFPPL.CO.IN served on article pages are served on a random basis, in rotation with Red Flower Publication advertising and recruitment advertising. The random placement algorithm does not permit any commercial ad to be targeted to any specific article or any specific user or group of users. Advertisers have no advanced knowledge and no control over ad placement. Neither the Publisher nor its publications endorse any company, product, or service.
• Advertisers should make available to Red Flower Publication the marketing authorization and summary of product characteristics when submitting their advertisement. In the case of drug advertisements, the full generic name of each active ingredient should appear. Each page of an advertisement for a prescription-only medicine should be clearly labeled as intended for health professionals.
• If any advert is requested outside of Red Flower Publication standard advertising positions then a request should be made to editorial who will respond with a full and final decision within two business days.
• We partner with third-party advertising companies to serve ads and/or collect certain information when you visit our website. These companies may use cookies or web beacons to collect non-personally identifiable information [not including your name, address, email address or telephone number] during your visit to this website to help show advertisements on other websites also likely to be of interest to you. To learn more about this “behavioral advertising” practice or to opt-out of this use of your anonymous information.
• Advertisements and editorial content must be clearly distinguishable. Red Flower Publication will not publish “advertorial” content, and sponsored supplements must be clearly indicated as such. If a supplement did not undergo peer review or underwent a peer review-process different from the rest of the journal that should be explicitly stated.
• Editorial decisions will not be influenced by current or potential sponsors and advertisers, and will not be influenced by marketing decisions. Advertisers and sponsors have no control or influence over the results of searches a user may conduct on the website by keyword or search topic.
• Recruitment ads must be non-discriminatory and comply with all applicable laws and regulations. Ads that discriminate against applicants based on sex, age, race, religion, marital status or physical handicap will not be accepted. Non-India recruitment advertisers are required to confirm in writing that they are equal opportunity employers.
• Red Flower Publication will not accept advertising for products or services known to be harmful to health (e.g. tobacco and alcohol products).
• Information about complaints concerning advertisements will be included in the Advertisements page.

Advertising complaints policy

Advertiser may cancel the entire Insertion Order, or any portion thereof, as follows:

• On written notice to Publisher given 21 or more days before the start date. With cancellations inside 21 days of the start date, advertiser will be responsible for 50% of the IO amount that was reserved for delivery.
• Flat fee-based or fixed placement programs (including, but not limited to, Roadblocks, Specialty Packs, and other Sponsorships:
• On written notice to Publisher given 30 or more days before the start date. With cancellations inside 30 days of the start date, advertiser will be responsible for 50% of the IO amount that was reserved for delivery.

Advertising complaints policy

Please send any complaints about advertising to: info@rfppl.co.in

Advertisement Standard Code of India (ASCI)
The Advertisement Standard Code of India investigates complaints about published medicines advertisements and ensures compliance with the India Codes of Advertising and Sales Promotion which include a section on medicines advertising. It also monitors advertising in the press, direct marketing and sales promotion and on the Internet. Advertisements directed at health professionals are exempt from the India Codes of Advertising and Sales Promotion.

The Prescription Medicines Code of Practice Authority (PMCPA)
Complaints about the advertising of medicines supplied on prescription are considered by the Prescription Medicines Code of Practice Authority under the OPPI Code of Pharmaceutical Practices. Complaints which are made under the Code about promotional activities and promotional material are considered by the Code of Practice Panel, the decisions of which can be appealed to the Code of Practice Appeal Board. Reports on completed cases are published quarterly in the Code of Practice Review.

Policy corrected as of 30 November, 2022

ASCI: India's Advertising Regulatory Framework

Advertising, generally speaking, is the promotion of goods, services and ideas, usually performed by an identified sponsor. Marketers see advertising as part of an overall promotional strategy. Other components of the promotional mix include publicity, public relations, personal selling, and sales promotion.

The Advertising Standards Council of India (ASCI), established in 1985, a body committed to the cause of Self-Regulation in Advertising, ensuring the protection of the interests of consumers to maintain and enhance the public's confidence in Advertising.

This write up attempts to explicate the initiative taken by ASCI in controlling and promoting the concept of fair advertising practices in India and its impact on the advertisements prevailing in the Pharmaceutical Sector at present.

In regards to promote fair practices of advertisement in the Indian market and protect the right of customers as guaranteed under the Consumer Protection Act, 1986, ASCI had come up with the regulatory mechanism termed as "Code for Self-Regulation in Advertising"["Code"] with the prime objectives to identify and control the content of advertisements so that they are not offensive and illegal in nature and should not intent to misrepresent the customers so as to achieve fair advertising practices in the scenario of Indian market by ensuring the following basic guidelines:-

To ensure the truthfulness and honesty of representations and claims made by advertisements and to safeguards against misleading advertisement.

To ensure that advertisements are not offensive to generally accepted standards of public decency.
To safeguard against the indiscriminate use of advertising for the promotion of products which are regarded as hazardous to society or to individuals to a degree or of a type this is unacceptable to society at large.

To ensure that advertisements observe fairness in competition so that the consumer's need to be informed on choices in the market-place and the canons of generally accepted competitive behaviour in business is both served.

The code brings into its purview all those advertisers, advertising agencies, media or such other individuals who commission, create, place or publish any advertisement or assist in the creation or publishing of any advertisement which is in contravention of this Code and applies to advertisements read, heard or viewed in India even if they originate or are published abroad so long as they are directed to consumers in India or are exposed to significant number of consumers in India.

The Code is divided into IV chapters and the onset of it defines "advertisement", "product", "consumer", "advertiser", "advertising agency", "media", etc. The Code not only includes all form of paid- for communication, addressed to the Public or a section of it but does not exempt even those form of communication which is carried free-of-charge for any reason in the normal course which is recognized as an advertisement by the general public. Hence, advertisers or advertising agency or media or any such related person cannot defend himself/itself from the purview of the Code on the ground that he/it was not indulged in a communication for commercial promotion of any product and the communication was meant only for general reference.

ASCI and its reach on Pharmaceutical/ Allied health care Industry

Recently ASCI upheld approximately 36 complains in the category of Pharmaceuticals companies and Healthcare sector held for violation of the Code.

In an advertisement of the pain relief ointment Volini, Ranbaxy Laboratories Ltd. claimed as "99% doctors have used Volini to relieve their pain" and "Volini No.1 doctors' prescribed pain reliever since last 12 years".

Dabur India Ltd's Dabur Chyawanprash print ad claimed that "Dabur Chyawanprash provides 3 times more immunity", "Helps improve the ability to fight illness by 3 times", "ONLY Dabur Chyawanprash provides immunity.

In the above matters, the advertiser was not able to substantiate the claim with necessary support and data and the ad were considered as contravention of the Code.

The National Advertising Monitoring Service (NAMS)

In order to maintain a track on misleading advertisements which harm the interests of consumers, ASCI announced an initiatives of a mechanism called National Advertising Monitoring Service (NAMS) which will work in partnership with TAM Media Research and will identify advertisements which are in potential violation of Chapter 1 of ASCI Code and will monitor ads in the sectors covering Auto, Banking, Financial Services & Insurance, FMCG (including F&B), Consumer Durables, Educational Institutions, Health Care Products & Services, Telecom and Real Estate sectors. The scope of work will cover the tracking of more than 30 newspapers (all editions) which contribute to over 80 per cent of national newspaper readership and all TV channels in all Indian languages. The mechanism will work on three-fold steps initiating from tracking advertisements that is seen as being potentially violating Chapter 1 of ASCI Code which will then be forwarded to ASCI on a weekly basis, post which ASCI would process them according to its normal complaint procedure involving its Consumer Complaints Council (CCC) for adjudication.

Keeping in view the initiatives undertaken by ASCI in the recent past and irrespective of the fact that the Code introduced by ASCI is voluntary in nature, the advertisers ought to give regard to such Code at the time of publishing their advertisements since if any advertiser fails to comply with the CCC decision in writing on a complaint upheld against a Press Ad, the ASCI has option to inform the Press Council of India and Ministry of Information & Broadcasting about the print Ad contravening the ASCI Code and such action may dent the reputation of the concerned advertiser.

Last updated 22 June 2024